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Introduction
Multiple myeloma (MM) is characterized by anemia,
increased susceptibility to infections, and severe pain as a
result of osteolytic lesions. The destruction of bone is the
result of multiple factors and causes several skeletal complica-
tions such as bone pain, pathological fractures, spinal cord
compression, and hypercalcemia.1,2 Many of these complica-
tions are associated with significant morbidity and can have
a negative impact on survival.2 To reduce and delay the skele-
tal morbidity caused by MM, treatment with bisphospho-
nates (BP) has become the standard of care for patients with
MM and bone disease.3
Osteonecrosis of the jaw (ONJ) is an uncommon but poten-
tially serious complication of intravenous BPs, which is char-
acterized by the presence of exposed bone in the mouth.4,5
Currently, the cause of ONJ is not certain and is likely multi-
factorial. The risk for ONJ increases the longer BP treatment
is continued and has been shown to be 5-15% at four years.2
Although ONJ has been described during therapy with any
BP, the possibility of developing ONJ may increase with the
use of the more potent BPs, with a higher incidence for zole-
dronic acid (ZOL).6-8
Recently, several guidelines for the prevention, diagnosis,
and management of ONJ have been released. These mainly
focus on the relevant clinical aspects of prevention.1
Conversely, there is little data concerning biological markers
that could help to predict which of these patients receiving BP
therapy are at risk of developing this complication. 
With the availability of the human genome sequence, the
impact of single nucleotide polymorphism (SNP) variations
on disease became a primary focus in many research areas.
Effects on RNA stability, splicing, or mRNA folding have
been suggested as potential mechanisms to explain how SNPs
can affect drug sensitivity or biological functions. In MM,
Sarasquete et al. published a study using the Affymetrix
GeneChip Mapping 500K showing that the presence of one or
two minor alleles of the cytochrome P450, subfamily 2C
polypeptide 8 gene (CYP2C8) SNP rs1934951 was an inde-
pendent prognostic marker associated with development of
ONJ in MM patients treated with BPs.9 CYP2C8 gene,
mapped in chromosome 10q23, codify for a significant
enzyme in metabolism of numerous therapeutic drugs.10,11
The aim of this study was to validate the incidence of SNP
rs1934951 polymorphism in an independent series of patients
with MM treated with BP therapy.
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Osteonecrosis of the jaw is an uncommon but potentially seri-
ous complication of bisphosphonate therapy in multiple
myeloma. Previous studies showed that the presence of one or
two minor alleles of the cytochrome P450, subfamily 2C
polypeptide 8 gene (CYP2C8) polymorphism rs1934951 was
an independent prognostic marker associated with develop-
ment of osteonecrosis of the jaw in multiple myeloma patients
treated with bisphosphonates. The aim of this study was to
validate the frequency of SNP rs193451 in 79 patients with
multiple myeloma. In 9 (22%) patients developing osteonecro-
sis of the jaw, a heterozygous genotype was found, in contrast
with those who did not develop osteonecrosis of the jaw (n=4,
11%) or healthy individuals (n=6, 13%). We found no differ-
ences in the cumulative risk of developing osteonecrosis of the
jaw between patients homozygous and heterozygous for the
major allele. We were unable to confirm a significant associa-
tion between this polymorphism and the risk of developing
osteonecrosis of the jaw. 
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ABSTRACT
Design and Methods
Two series of patients from the University Hospital La Fe
(Valencia, Spain, n=59) and the Alexandra General Hospital
(Athens, Greece, n=20) diagnosed with MM with and without
ONJ were pooled and studied for the incidence of the rs1934951
polymorphism. Clinical and biological characteristics of the
patients at diagnosis and their response to therapy were homoge-
neous between both series (Table 1). All together, a total of 79
patients with symptomatic MM diagnosed according to the
International Myeloma Working Group criteria12,13 between 1993
and 2008, and receiving treatment with BPs constitute the basis of
the present report. Those patients included in the study and diag-
nosed before 2003 started BP treatment from this date on. Forty-
two out of the 79 patients had ONJ and the remaining 37 did not
develop ONJ. For all patients, diagnostic procedures for ONJ were
carried out by stomatologists with extensive experience in the
diagnosis and management of this complication. ONJ was defined
as a non-specific necrotic lesion of bone tissue that occurred spon-
taneously or after a dental procedure without any evidence of
healing of the mucosal covering for at least eight weeks. In keep-
ing with the guidelines of the Declaration of Helsinki, this retro-
spective non-interventional study was conducted with the
approval of the internal review board of the Bioethics and Medical
Research at the University Hospital La Fe. All patients received BP
therapy with ZOL alone (median duration of treatment 18
months, range 8-84 months). 
Using dbSNP, the International HapMap Project, Applied
Biosystems’ SNP Browser and the UCSC Genome Browser, all
functional information and frequency data in the polymorphic
range were compiled, i.e. the frequency of the less common allele
in a Caucasian population from the SNP selected for this study.
Additionally, samples from 45 healthy volunteers provided by the
Biobanco Hospital La Fe were analyzed for the presence of
CYP2C8 polymorphisms to determine the polymorphic range in
the general Spanish population and to confirm that there were no
differences from the reported Caucasian population series. DNA
samples were extracted from whole peripheral blood or serum
blood by standard procedures. The SNP rs1934951 was analyzed
by a TaqMan® assay method (TaqMan® SNP genotyping Assay,
Applied Biosystems. Assay Reference C____361409_1_). The
manufacturer’s protocols were followed, and samples were run in
96-well plates and read on LightCycler 480 Endpoint Genotyping
Software.
Fisher’s exact test was used to test for the allelic association
between SNP rs1934951 and ONJ. Unadjusted time-to-event
analyses were performed using the Kaplan-Meier14 estimate and
log rank tests for comparisons15. The probability of ONJ was also
estimated by the cumulative incidence method, and univariate
comparison between the curves was performed using Gray’s
test16. All descriptive statistics and tests were performed using the
statistical SPSS package, version 17.0 (SPSS Inc., Chicago, IL, USA)
and R 2.7.2 software package. 
P<0.05 was considered significant.
Results and discussion 
The series included 45 (54%) males and 38 (46%)
females with a median age of 62 years (range 26-87 years).
The median follow up was 84 months (range 10-256
months). Homozygous genotype for the major allele
(CYP2C8CC) was the most frequent genotype in the three
populations studied and was observed in 32 (76%)
patients with ONJ, in 33 (89%) patients without ONJ, and
in 39 (86%) healthy volunteers. These proportions were
somewhat higher than those previously reported in SNP
databases (Table 2). Conversely, heterozygous genotype
(CYP2C8CT) was present in 9 patients with ONJ (22%), in
4 patients without ONJ (11%), and in 6 healthy volunteers
(13%). Finally, only one of the individuals analyzed was
found to be homozygous for the T allele (Table 1). Thus,
although roughly twice the number of the MM patients
developing ONJ showed heterozygous genotype
CYP2C8CT as compared with MM patients who did not
develop ONJ or healthy individuals, these differences did
not reach statistical significance (P=0.13). These results
contrast with those reported by Sarasquete et al. who
found a 66% of heterozygous genotype CYP2C8CT in MM
cases with ONJ versus 25% of controls.9 Additionally, they
also found 14% homozygous for the CYP2C8TT allele
within the ONJ group versus 0% within the controls.9
Perhaps the limited number of cases in both groups could
have influenced the results; however, our P values are very
different from those related to the comparisons made in
the previously published report by Sarasquete et al.9
These borderline results meant no concrete conclusions
could be drawn. We, therefore, estimated the cumulative
incidence of developing ONJ in patients with CYP2C8CT
genotype and in patients with CYP2C8CC genotype. At
three years, actuarial risk for patients with CYP2C8CT
genotype was 35% and for those with CYP2C8CC 53%,
with no statistically significant differences observed.
Table 1. Main clinical and biological characteristics of the patients.
MM patients MM patients P
with ONJ without ONJ
Age, years 61 (26-82) 61 (40-87)
Sex (male/female) 23/19 18/19 0.587
M-protein  (IgG/IgA/light chain/IgD) 30/5/5/2 22/5/9/1 0.494
Durie/Salmon stage (I/II/III) 7/12/18 2/13/19 0.256
ISS stage (1/2/3) 7/12/15 8/10/8 0.513
Type of first-line therapy 
Chemotherapy 
Thalidomide-dexamethasone 23/15 20/17 = 0.571
Autologous transplantation 24/14 16/21 = 0.084
Yes/no 28/12 25/12 = 0.750
Table 2. Allelic and genotypic distribution of the CYP2C8 SNP rs1934951.
Type of polymorphism N (%) TOTAL CC CT TT P C T P
Patients with ONJ N (%) 42 32 (76) 9 (22) 1 (2) 73 (87) 11 (13)
Patients without ONJ N (%) 37 33 (89) 4 (11) 0 (0) 0.131 70 (95) 4 (5) 0.099
Healthy volunteers N (%) 45 39 (87) 6 (13) 0 (0) 0.207 84 (93) 6 (7) 0.153
SNPdb on NCBI* N (%) 120 56 (67) 23 (28) 4 (5) 0.313 135 (83) 27 (17) 0.462
* Utah residents with Northern and Western European ancestry from the CEPH collection. (http://www.ncbi.nlm.nih.gov/projects/SNP)
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The two studies used slightly different methodologies.
Besides these, several factors could explain, at least in part,
the differences observed in the CYP2C8 allele proportion
between our series and in the previous report by
Sarasquete et al.9 First, there may have been a bias in
patient selection between both series due to the small
numbers of patients. Second, patients in the previous
series were uniformly treated with polychemotherapy fol-
lowed by autologous transplant whereas in our series
patients received different induction regimens, including
new drugs (thalidomide). Additionally, all patients in our
study received ZOL as BP therapy whereas in the series by
Sarasquete et al., the main BP administered was
pamidronate.9 Finally, in our series we could not evaluate
the potential role of oral risk factors (oral surgery, previous
dental assessment, control of pre-existing implants and
prosthesis) or the application of strategies to prevent ONJ
in this group of patients.17 This could help to explain the
different results observed in the two studies. Overall,
although our results showed a trend towards a higher pro-
portion of the SNP rs1934951 polymorphism on CYP2C8
gene in those patients developing ONJ, there was no sig-
nificant difference in the cumulative risk compared with
patients with the homozygous major allele. In conclusion,
we were unable to confirm in an independent series a sig-
nificant association between polymorphisms in the
CYP2C8 gene and the risk of developing osteonecrosis of
the jaw in patients with MM receiving treatment with BP.
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